BiomX Inc. (PHGE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q2 '26: 332K Q2 '26

Gross Profit Quarterly

0 35K 70K 105K Q2 '26: 97K Q2 '26

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -9.8M Q4 '21: -9.8M Q1 '22: -7.8M Q2 '22: -7.3M Q3 '22: -6.5M Q4 '22: -5.6M Q1 '23: -6.2M Q2 '23: -6.1M Q3 '23: -7.8M Q4 '23: -5.3M Q1 '24: -6.8M Q2 '24: -9.7M Q3 '24: -11.3M Q4 '24: -16.7M Q1 '25: -7.8M Q2 '25: -7.4M Q3 '25: -8.5M Q4 '25: -17.7M Q1 '26: -1.3M Q2 '26: -5.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q4 '21: -10.5M Q1 '22: -8.2M Q1 '22: -8.2M Q2 '22: -7.5M Q3 '22: -6.8M Q4 '22: -5.9M Q1 '23: -6.4M Q2 '23: -6.4M Q3 '23: -7.9M Q4 '23: -5.5M Q1 '24: -17.3M Q2 '24: 4.5M Q3 '24: 9.6M Q4 '24: -14.5M Q1 '25: -7.7M Q2 '25: -6M Q3 '25: -9.2M Q4 '25: -13.3M Q1 '26: -19.1M Q2 '26: -3.8M Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 80K 160K 240K Q2 '26: 235K Q2 '26

Operating Cash Flow Quarterly

-12M -8M -4M 0 4M 8M 12M Q3 '21: -5.7M Q4 '21: -9.1M Q1 '22: -7.4M Q2 '22: -9.1M Q3 '22: -5.5M Q4 '22: -7.2M Q1 '23: -5M Q2 '23: -4.1M Q3 '23: -5.9M Q4 '23: -6.2M Q1 '24: -11.4M Q2 '24: -11.2M Q3 '24: -8.1M Q4 '24: -6.3M Q1 '25: -8.7M Q2 '25: -6.1M Q3 '25: -7.2M Q4 '25: -4.4M Q1 '26: -5.4M Q2 '26: -1.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q4 '19: -7.4M Q1 '20: -7.1M Q2 '20: -4.7M Q3 '20: -6.1M Q4 '20: -7.5M Q1 '21: -7.8M Q2 '21: -7.2M Q3 '21: -7M Q4 '21: -9.2M Q1 '22: -7.4M Q2 '22: -9.1M Q3 '22: -5.5M Q4 '22: -7.2M Q1 '23: -5.1M Q2 '23: -4.1M Q3 '23: -6M Q4 '23: -6.2M Q3 '24: -8.1M Q4 '24: -6.3M Q4 '25: -4.4M Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 24.3M Q3 '21: 27.1M Q1 '22: 29.8M Q2 '22: 29.8M Q3 '22: 29.9M Q1 '23: 32.1M Q2 '23: 51.6M Q3 '23: 6.1M Q1 '24: 6.2M Q2 '24: 10.8M Q3 '24: 16.4M Q1 '25: 23.1M Q2 '25: 1.6M Q3 '25: 31.4M Q1 '26: 2.6M Q2 '26: 10.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 25.00 50.00 75.00 Q3 '19: 7.39 Q4 '20: 1.30 Q1 '21: 1.39 Q2 '21: 1.42 Q3 '21: 1.41 Q4 '21: 1.38 Q1 '22: 1.30 Q2 '22: 1.25 Q3 '22: 1.11 Q4 '22: 0.95 Q1 '23: 0.88 Q2 '23: 0.75 Q3 '23: 1.82 Q4 '23: 2.43 Q1 '24: 5.01 Q2 '24: 5.58 Q3 '24: 3.97 Q4 '24: 59.02 Q1 '26: 32.72 Q2 '26: 29.43 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.